Competitive Therapeutic Landscape Assessment
Global Pharmaceutical Company
Client Problem
Model the US NSCLC targeted therapy market and predict its anticipated (3-5 year) developments
Understand how further segmentation of the targeted therapies will impact market share of entrenched checkpoint inhibitors across lines of therapy
EmPartners' Approach
We conducted a thorough literature review to understand the biomarker mutation prevalence in NSCLC patients in the US
We then created an exhaustive landscape of all novel molecules and MOAs in development for NSCLC to understand which will address areas of unmet need or new biomarkers across different lines of therapy
Combining this information, we estimated how each potential new approval will detract from the remaining non-biomarker-selected NSCLC population
Client Impact
Client received a comprehensive near-to-mid-term view of upcoming targeted therapy agents for NSCLC together with the anticipated effects of each potential approval on market
size for existing CPI products
This was used to aid internal commercial planning and decision making on investment prioritization across the client portfolio
